Active — Not RecruitingNot Applicable

Outcomes of Arterial Allografts Preserved at +2 to +8°C for Revascularization in Septic Settings

France40 participantsStarted 2024-06-03

Plain-language summary

This study does not modify patient management or treatment. All patients undergoing treatment with an arterial allograft preserved at +2/+8°C as part of an arterial revascularization in a septic environment in either of the two centers between January 2024 and January 2025 will be included. Imaging exams and clinical follow-up data will be analyzed. Reinterventions and causes of death will be recorded. All imaging required for the 6-month follow-up is routinely performed as part of standard care. No modification of patient management is planned.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient * Requiring revascularization in a septic or high-risk septic environment * With an estimated life expectancy of 12 months or more based on medical and surgical assessment * Informed about the study Exclusion Criteria: * Pregnant women * Individuals for whom regular medical follow-up cannot be ensured

What they're measuring

To evaluate the 6-month primary patency of revascularizations using arterial allografts preserved at +2 to +8°C

Timeframe: 6 month

Trial details

NCT IDNCT06963255

SponsorHospices Civils de Lyon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-01

View on ClinicalTrials.gov More Revascularization in a Septic or Potentially Septic Environment trials